22-May-2026
TipRanks (Fri, 22-May 7:40 AM ET)
Globe Newswire (Wed, 20-May 9:00 AM ET)
Indivior’s Earnings Call Highlights SUBLOCADE-Driven Surge
TipRanks (Wed, 20-May 2:17 AM ET)
Indivior to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 14-May 7:00 AM ET)
Indivior Announces $175 Million Accelerated Share Repurchase
Globe Newswire (Mon, 4-May 7:00 AM ET)
Indivior Ups Full-Year Guidance After Record Q1 Growth in SUBLOCADE and EBITDA
Market Chameleon (Thu, 30-Apr 4:23 AM ET)
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Globe Newswire (Thu, 30-Apr 7:00 AM ET)
Globe Newswire (Fri, 24-Apr 11:00 AM ET)
Globe Newswire (Thu, 16-Apr 2:30 PM ET)
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Globe Newswire (Thu, 9-Apr 7:00 AM ET)
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals trades on the NASDAQ stock market under the symbol INDV.
As of May 22, 2026, INDV stock price climbed to $37.53 with 980,594 million shares trading.
INDV has a beta of 0.39, meaning it tends to be less sensitive to market movements. INDV has a correlation of 0.01 to the broad based SPY ETF.
INDV has a market cap of $4.44 billion. This is considered a Mid Cap stock.
Last quarter Indivior Pharmaceuticals reported $317 million in Revenue and $.96 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.30.
The top ETF exchange traded funds that INDV belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
INDV has outperformed the market in the last year with a return of +234.8%, while the SPY ETF gained +29.1%. In the last 3 month period, INDV beat the market returning +10.7%, while SPY returned +8.4%. However, in the most recent 2 weeks INDV has underperformed the stock market by returning -5.0%, while SPY returned +1.1%.
INDV support price is $36.49 and resistance is $38.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INDV shares will trade within this expected range on the day.